Aptose Biosciences (NASDAQ:APTO) Price Target Raised to $6.00 at HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its price objective boosted by equities research analysts at HC Wainwright from $2.00 to $6.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 80.18% from the company’s previous close.

Several other analysts have also issued reports on APTO. StockNews.com started coverage on Aptose Biosciences in a report on Thursday. They set a “sell” rating for the company. Alliance Global Partners raised shares of Aptose Biosciences to a “strong-buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Aptose Biosciences currently has an average rating of “Moderate Buy” and an average price target of $112.00.

Aptose Biosciences Stock Down 10.0 %

APTO traded down $0.37 during trading on Friday, hitting $3.33. The company’s stock had a trading volume of 27,110 shares, compared to its average volume of 224,082. The business’s 50 day simple moving average is $4.63 and its 200-day simple moving average is $7.59. The firm has a market cap of $7.13 million, a PE ratio of -1.12 and a beta of 1.14. Aptose Biosciences has a one year low of $2.39 and a one year high of $51.61.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 703,384 shares of the biotechnology company’s stock after purchasing an additional 301,634 shares during the period. Sigma Planning Corp owned approximately 1.17% of Aptose Biosciences worth $158,000 at the end of the most recent quarter. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.